Jinbo is situated in 18 Jingbei Street, Economic and Technological Development Zone, Taiyan City. The floor area is 30mu. It is a modern biomedicine enterprise engaged in R&D, production and distribution. With the business orientation of research, development and industrialization of genetically engineered drug, genetically engineered cosmetics, and bioprotein preparation, the company mainly engages in researching, developing, piloting, manufacturing and marketing biological medicines.
Jinbo owns international advanced technology, first-class R&D level, and highly-qualified team. It has established close cooperation relationships with Tsinghua University, Fudan University, Chinese Academy of Sciences, New York University, and other research and development organizations. Jinbo owns complete intellectual property, and it mainly engages in researching “functional protein”. In 2011, the company was rated as “national high-tech enterprise”. Jinbo has 8 invention patents. The company has developed “anti-HPV-J8 protein” and recombinant human collagen” with Jiang Shibo team of Fudan University. In 2013, the company undertook “the 12th Five-Year Plan” mega project of science research “prevention and cure of serious infectious diseases such as Aids and viral hepatitis” (No. is 2013ZX10001006-004) with Fudan University. In May 2015, the company signed “development and application of technologies of phage fully human antibody library” with Fudan University. Insisting on objective of developing by innovation, serving clients by technological progress, the company strives to be a leading enterprise in the field of “function protein”.
Jinbo was founded in March 2008. In 2015, the company started the Three Board listing project, and it finished shareholding reform on March 27, 2015. On July 9, 2015, the company got the approval of National Equities Exchange and Quotations. Shock abbreviation is “Jinbo Biology”, and stock code is 832982.
As a high-tech enterprise in bioengineering industry, the company is focused on producing biological medical products with high technological content. Moreover, Jinbo has established technology risk investment mechanism to attract and encourage talents. The company will established an international advanced innovation and development platform.